Stockscreener 앱 받기
767.76
1.35%
10.22
시간 외 거래:
767.76
전일 마감가:
$757.54
열려 있는:
$811.35
하루 거래량:
8.93M
Relative Volume:
2.49
시가총액:
$690.46B
수익:
$40.86B
순이익/손실:
$8.37B
주가수익비율:
141.67
EPS:
5.4193
순현금흐름:
$-2.28B
1주 성능:
-2.71%
1개월 성능:
+1.90%
6개월 성능:
-13.34%
1년 성능:
+34.65%
1일 변동 폭
$766.61
$811.35
1주일 범위
$752.39
$811.35
52주 변동 폭
$567.02
$972.53
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Novo Nordisk raises Eli Lilly post CagriSema data (NVO:NYSE) - Seeking Alpha
2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves - The Motley Fool
Novo obesity data positive for Eli Lilly and Amgen, says UBS - Yahoo Finance
FDA says knockoff versions of Lilly obesity drug must come off the market - Wyoming Tribune
Is Now a Good Time to Buy the Dip in Eli Lilly Stock? - AOL
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea - ABC News
The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next - MSN
Eli Lilly given green light in US to treat sleep disorder with weight-loss drug - Financial Times
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea - Reuters
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea By Reuters - Investing.com
Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S. - STAT
Eli Lilly's Zepbound gains sleep apnea indication (LLY:NYSE) - Seeking Alpha
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea - The Denver Gazette
Lilly’s Zepbound Grabs First Drug Approval for Sleep Apnea in US - Bloomberg
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. - CNBC
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity - Investors | Eli Lilly and Company
Eli Lilly and Company (NYSE:LLY) Trading 4.2% HigherHere's Why - MarketBeat
Nvidia, Eli Lilly lead Friday's market cap stock movers By Investing.com - Investing.com Canada
Nvidia, Eli Lilly lead Friday's market cap stock movers - Investing.com India
Lilly Cements Weight Loss Lead After Novo Trial Setback - Bloomberg
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now - Seeking Alpha
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up - The Motley Fool
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it - CNN
Eli Lilly and Company (NYSE:LLY) Shares Gap UpHere's What Happened - MarketBeat
Eli Lilly, Avago lead market cap stock movers this Friday - Investing.com
In weight loss battle, Novo and Lilly face growing offensive from licensed copies - Reuters
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List - Yahoo Finance
Stocks to Watch Friday: Trump Media, Novo Nordisk, Eli Lilly, Tesla - The Wall Street Journal
Eli Lilly shares reiterate buy rating on Phase 3 study results - Investing.com
Citi Reiterates Buy Rating on Eli Lilly (LLY) - StreetInsider.com
FedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fall - Investing.com
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation - Yahoo Finance
Eli Lilly (LLY) stock: Why It’s a strong buy amid breakthrough developments - The Africa Logistics
Bernstein optimistic on Eli Lilly shares despite limited near-term impact from Tirzepatide - Investing.com
Novo Nordisk sinks on latest data, Lilly gains - Investing.com
FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next - Yahoo Finance
US FDA says Lilly's weight-loss drug shortage is resolved - Reuters.com
Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch
Jim Cramer on Eli Lilly and Company (LLY): ‘I See Things Going Back To Normal For Eli Lilly’ - Insider Monkey
Eli Lily GLP-1 shortage ends, FDA says: Hims & Hers stock falls - Yahoo Finance
Eli Lilly and Company (NYSE:LLY) Shares Down 1.2%Should You Sell? - MarketBeat
US FDA says Lilly’s weight-loss drug shortage is resolved - CNN
Eli Lilly dips despite FDA confirming shortage of GLP-1 tirzepatide is over - Investing.com
Eli Lilly’s (NYSE:LLY) Zepbound Shortage Over, Says FDA - TipRanks
Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copies - Bloomberg
FDA Says Shortage of Eli Lilly’s Zepbound is Over, But Gives Compounders a Grace Period - Yahoo! Voices
Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copycats - The Business of Fashion
Lilly’s US weight-loss drug shortage ends, curtailing copycats - Detroit News
Eli Lilly’s Zepbound Shortage Is Officially Over, FDA Says - Yahoo! Voices
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook - Seeking Alpha
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.83%
0.62%
자본화:
|
볼륨(24시간):